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  23 
ABSTRACT 24 
Background. We have co-designed a tailored blended physiotherapy intervention for people 25 
with Progressive Multiple Sclerosis (PwPMS) who often struggle to access support for physical 26 
activity. Underpinned by self-management principles, the Lifestyle, Exercise and Activity 27 
Package for people with Multiple Sclerosis (LEAP-MS) intervention, incorporates face-to-face 28 
or online physiotherapy coaching sessions with an accompanying online physical activity 29 
platform. The LEAP-MS platform is a multi-user system enabling user and physiotherapist to 30 
co-create activity plans. The LEAP-MS platform consists of an information and activity suite, 31 
interactive components enabling selection of exercises into an activity programme, goal setting, 32 
and activity logging. The platform also facilitates online remote support from a physiotherapist 33 
through an embedded online messaging function. We aim to evaluate the LEAP-MS platform 34 
in a feasibility trial.   35 
 36 
Methods. LEAP-MS will be evaluated within a single arm feasibility study with embedded 37 
process evaluation. After registration and initial eligible screening, 21 participants will be 38 
required to complete baseline self-completion measures.  This will be followed by an initial 39 
home-based or online coaching session with a physiotherapist (who has received tailored self-40 
management and digital resource training) and access to the online intervention for an initial 41 
three-month period. During this period participants are given the option to request up to five 42 
further home-based or online physiotherapy coaching sessions. Follow-up questionnaires and 43 
semi-structured interviews will be administered three months after baseline with participants 44 
and intervention physiotherapists. The LEAP-MS platform will be available to participants for 45 
LEAP-MS: Protocol for a Single-Arm Feasibility Study. 
 
3 
a further three months. Usage of the LEAP-MS platform will be tracked during the full six-46 
month period and final follow up will be conducted six months after baseline. 47 
 48 
Discussion. Feasibility outcomes (recruitment, retention, intervention uptake and safety) will 49 
be reported. The process evaluation will be undertaken to identify possible mechanisms for any 50 
observed effects. The data will inform full scale evaluations of this co-produced, blended 51 
physiotherapy intervention. 52 
 53 
Trial registration:  54 
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BACKGROUND.  67 
Multiple sclerosis (MS) is the most common disabling neurological disease among young 68 
adults (1) affecting an estimated 107,000 people in the UK (2). MS is characterised by focal 69 
areas of inflammatory demyelination within the central nervous system. In the early phase of 70 
MS, most people experience discrete episodes of neurological dysfunction (relapses). 71 
However, around half of people with relapse-onset MS tend to develop an insidious 72 
deterioration in disability after 30 years from onset, which is described as secondary 73 
progressive disease (3,4). In addition, around 10% of people with MS do not experience 74 
relapses at onset, but rather present with an insidious accumulation of neurological disability, 75 
which continues to progress with or without superimposed relapses, termed primary 76 
progressive MS (3,5).  77 
 78 
In the UK it is estimated that 10-15,000 have primary progressive MS (6) and 38,000 have 79 
secondary progressive MS (7, 8).   People with progressive MS (PwPMS) tend to have higher 80 
levels of disability than those with relapsing-remitting MS, often have high health and social 81 
care needs and self-report low health related quality of life (9, 10). PwPMS experience a wide 82 
range of symptoms including motor, sensory, visual, bowel and bladder dysfunction (11).  83 
 84 
Physiotherapists play a central role as part of a multidisciplinary team of healthcare 85 
professionals who support people with progressive multiple sclerosis in the management of 86 
their symptoms (12).  Primarily focussed on maintaining, adapting or enhancing physical and 87 
sensory capabilities of individual patients, physiotherapy has been shown to be effective in, for 88 
example, improving balance (13), mobility (14), and spasticity (15) with people with MS. As 89 
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part of their therapeutic toolkit, physiotherapists use exercise and have expertise in supporting 90 
and promoting physical activity (16).   91 
 92 
Physical activity is “any bodily movement produced by skeletal muscles that requires energy 93 
expenditure” (17) and relates to activities of daily living which are conducted through 94 
movement and activities with physical/movement components which are carried out as part of 95 
work, leisure or recreation – including walking or wheeling, sports, play, etc.  The physical 96 
activities we undertake both define and can be shaped by our lifestyle – simply defined as the 97 
way in which we live – relating to everyday behaviours and activities including work, leisure 98 
and diet (18,19).  The interconnectedness of these concepts requires the context within which 99 
people live to be taken into consideration when exploring how to support people to be 100 
physically active.   101 
 102 
Regular physical activity is generally regarded to be an important component of the long-term 103 
management of MS.  Positive outcomes of regular physical activity include improved mobility, 104 
strength and cognition, and reduced fatigue (20-22). There are also well-established 105 
psychological and social benefits associated with physical activity in MS (23, 24) and engaging 106 
in regular physical activity is considered to be a positive way to cope with living with 107 
progressive MS (25, 26).  108 
 109 
Engaging with physical activity significantly enough to benefit from such outcomes, however, 110 
relies on changing behaviours.  Behaviour change theories (theories and models which seek to 111 
explain why people behave the way they do and what is required to alter what they do and how 112 
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they think) are therefore often selected to underpin the development and testing of physical 113 
activity interventions – known as ‘behaviour change interventions’ (27).  114 
 115 
Although physical activity interventions can be based on a plethora of behaviour change 116 
theories, aspects of social cognitive theory and self-regulation theory (28,29) are widely drawn 117 
upon.  The key constructs within these theories are those of self-efficacy and self-regulation.  118 
Self-efficacy is defined as ‘the belief in one's capabilities to organize and execute the courses 119 
of action required to manage prospective situations’ (28).  It forms part of self-regulation, the 120 
processes of ‘self-monitoring of one's behaviour, its determinants, and its effects; it also 121 
includes judgment in relation to personal standards and environmental circumstances; and 122 
affective self-reaction’ (29).  Methods used to implement these constructs overlap, and include 123 
goal setting, feedback and guided practice.  124 
 125 
Various physical activity interventions for people with MS have been reported in the literature, 126 
ranging from group-based to digital versatile disc (DVD) and web-based interventions (30-34). 127 
A recent systematic review which evaluated the effectiveness of behavioural change 128 
interventions aiming to increase activity and participation in people with MS found that short 129 
duration interventions incorporating goal setting, barrier identification and information 130 
provision increased physical activity (27). These, and more recent research exploring physical 131 
activity interventions and factors impacting physical activity levels for people with MS, 132 
highlight how developing self-determined and self-efficacious physical activity behaviours 133 
through goal setting, appropriate communication and self-monitoring are critically important 134 
determinants of sustained physical activity behaviour (35-37). 135 
 136 
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Despite the potential benefits of physical activity and the value placed on supporting people 137 
with MS to remain active, there remains little evidence about the benefits of physiotherapy or 138 
physical activity for PwPMS who have more advanced disability (38). Most research has 139 
focussed on patients who are ambulatory, despite non-ambulatory people with MS being those 140 
who are least likely to stay active (23, 39, 40). A systematic review (41) of physiotherapy 141 
interventions, including exercise therapy, for the rehabilitation of people with progressive 142 
multiple sclerosis published in 2016 reviewed 13 studies (of eight interventions) of variable 143 
methodological quality.  It concluded that physiotherapy and exercise interventions for PwPMS 144 
was potentially of benefit but that fully powered efficacy studies were required. Recently, a 145 
home-based, self-managed standing frame programme has been found to be effective in 146 
PwPMS (42) however, there is little research into physical activity interventions in PwPMS, 147 
which may be explained by difficulties recruiting or retaining individuals with advanced 148 
disability into research studies. These challenges, which may be explained by difficulties 149 
travelling to appointments and a high prevalence of fatigue and cognitive impairment, are the 150 
same ones that must be overcome to enable PwPMS to engage in sustained physical activity. 151 
Seeking sustainable, cost-effective interventions that facilitate access to physical activity for 152 
all remains a priority.   153 
 154 
Despite the limited evidence about the benefits of physical activity for PwPMS, we know that 155 
people with MS, including those with progressive MS, want to keep physically active and 156 
moving (25, 43).  However, people with MS, especially those who are more disabled, find it 157 
hard to start and to maintain activity (44).  Many require support to remain physically active 158 
and often do not receive enough support (44). When people with MS are asked about their 159 
needs, physiotherapist-led support for physical activity ranks highly (45-47) with many 160 
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needing support to identify physical activity that is suited to them (48,49). Physiotherapists’ 161 
training and experience mean that they are ideally placed to support physical activity and 162 
exercise prescription and are often promoted as exercise experts (50).  This expert role, 163 
however, may paradoxically foster reliance on physiotherapists and although many 164 
physiotherapists have a thorough knowledge of risk factors, pathology and their effects on all 165 
systems, they may not necessarily be confident in exercise physiology and prescription. Indeed, 166 
the first barrier to promoting activity in PwPMS may come not from the individual themselves, 167 
but from the professionals with whom they engage (51,52).  168 
 169 
Here we present the protocol for the LEAP-MS single arm feasibility trial and embedded 170 
process evaluation. Underpinned by social cognitive theory and self-regulation theory, taking 171 
a self-management approach - LEAP-MS is a co-designed blended physiotherapy digital 172 
intervention (53). Our primary objective is to establish the feasibility of the LEAP-MS 173 
intervention. Secondary to this, we will validate the underpinning intervention logic model 174 
through both qualitative assessment of intervention processes and descriptive evaluation of 175 
acceptability and patient-reported outcomes. 176 
 177 
METHODS.  178 
STUDY DESIGN SUMMARY AND SETTING 179 
This is a single arm feasibility study with an embedded process evaluation. Those who are 180 
eligible and consent to participate in the study will complete a series of self-completed 181 
assessments at baseline, 3 and 6 months; during this time they will also have access to the 182 
LEAP-MS blended physiotherapy intervention (see Figure 1; participant flow diagram). The 183 
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intervention will be delivered online and, where possible, face-face in participants homes. 184 
Home-based delivery is reliant upon the current COVID-19 pandemic social distancing 185 
requirements being lifted and/or local physiotherapy provision. 186 
 187 
The intervention comprises of physiotherapy coaching sessions (delivered via a secure web 188 
video conferencing system or in person where possible) and an online platform.  The online 189 
platform consists of a series of co-produced resources and functions.  These include online 190 
interactive education, an activity selection and planning tool, specifically developed for 191 
PwPMS and a participant-physiotherapist messaging system. The activity selection and 192 
planning tool includes tailored physical activity ideas and interactive functions enabling the 193 
development of personalised activity programmes, goal setting and activity logs. The online 194 
platform works in conjunction with remote or face-to-face coaching sessions and facilitates 195 
remote support (via the online platform messaging system) from trained physiotherapists. 196 
 197 
Figure 1: Participant flow diagram 198 
[Insert Figure 1 here] 199 
 200 
Population. We will recruit 21 participants with either primary or secondary progressive 201 
multiple sclerosis (as defined by the Lublin classification) (3) who are aged 18 or over and who 202 
have an Expanded Disability Status Scale (EDSS) score (54) between 6 and 8. The EDSS scale 203 
ranges from 0 to 10 in 0.5 unit increments that represent greater levels of disability.  EDSS 204 
steps 5.0 to 9.5 are defined by the impairment to walking – with people scoring 6-8 on the scale 205 
ranging from someone requiring a walking aid to walk 100m to someone who is largely 206 
restricted to a chair or wheelchair, but who maintains functional use of their arms.  Participants 207 
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will be required to have capacity to consent to study participation on their own behalf, and have 208 
access to mobile, wireless or wired internet connection at home. We will exclude any 209 
individuals with relapsing-remitting or non-progressive MS, those who are unable to 210 
understand written and spoken English, or those whose who are pregnant or planning a 211 
pregnancy. 212 
 213 
The sample size is based on the 95% confidence interval for an adequate proportion of eligible 214 
subjects being recruited (70%).  The lower 95% confidence interval is 50% which is the 215 
minimum acceptable recruitment proportion. 216 
 217 
Recruitment. There will be three routes for informing potential participants about the study: 218 
1. Eldrix HealthContact; 2. Outpatient physiotherapy services or 3. MS Society branch and 219 
national MS register publicity in the local region.   220 
1) Eldrix HealthContact is a tertiary centre MS database where PwPMS who meet the 221 
inclusion criteria and who have also given consent to be contacted about research will 222 
be identified by authorised Eldrix HealthContact users. A selection of those identified 223 
(based on EDSS scores in potentially eligible range) will be sent a study information 224 
sheet.  225 
2) Physiotherapists at the two participating Health Boards will screen all MS outpatients 226 
for eligibility during the recruitment phase. Those eligible and interested in 227 
participating will be provided with an information sheet about the study.  228 
3) Information about the study will be made available via the local branch of the MS 229 
Society (within the boundaries of the two participating Health Boards) and the UK MS 230 
Register inviting interested participants to complete the online expression of interest.   231 
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Those interested in participating will be required to complete an online expression of interest 232 
form and eligibility checklist via the LEAP-MS website. The expression of interest includes 233 
confirmation of MS diagnosis and EDSS self-completion. All participants recruited via the 234 
Eldrix HealthContact will have a consultant confirmed diagnosis of MS prior to entry into the 235 
database but recruitment via other routes relies on self-reporting.  Having a self-enrolment 236 
option however is aimed at enhancing accessibility and inclusivity. 237 
 238 
We will monitor population characteristics of those who express an interest in participating 239 
(age, gender and levels of disability). The expression of interest form will remain open until 240 
such time as eligibility has been confirmed for the entire recruited participant cohort.  This will 241 
take the form of a two-stage process.  First, prior to the initial target sample size being recruited, 242 
those who submit an expression of interest, will receive an automatically generated response 243 
from the system.  The message will thank them for their interest, explain that eligibility will be 244 
assessed in the order of expression of interest receipt and that the study team will contact them 245 
in due course.  Second, once eligibility has been confirmed for the entire participant cohort and 246 
the study has closed to recruitment, the expression of interest page will disabled, however 247 
interested individuals will be able to provide their contact details to receive study updates and 248 
results. 249 
 250 
Eligibility screening and informed consent. Those who complete an online eligibility 251 
checklist and are deemed potentially eligible will receive a telephone call from the research 252 
team, to discuss what participation in the study involves and given the opportunity to ask any 253 
questions.  Their eligibility will be checked during this call and fully confirmed by their 254 
physiotherapist at the first coaching session. Those participants who are interested in the study 255 
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will be directed back to the LEAP-MS website and provided with individual user details to 256 
complete an online consent form. Once the consent form has been submitted online, 257 
participants will be directed to complete the baseline assessment battery.   258 
 259 
Assessments.  All participants will be required to complete a range of patient-reported outcome 260 
measures directly online at baseline, 3 and 6-months post baseline (plus or minus 2 weeks; see 261 
Table 1: Schedule of enrolment, interventions and assessments).  Selected assessments were 262 
reflective of our logic model of change, linking performance objectives to the proposed 263 
intervention outcomes over the short and medium terms (53).  In the shorter term, we 264 
anticipated that adherence to the intervention would be achieved through enhanced self-265 
efficacy as assessed by the University of Washington 6-item short from self-efficacy scale 266 
(UW-SES-SF) (MS specific) (55).  This would then in turn influence the impact of ill-health 267 
on participation, activities and autonomy as measured by the Oxford Participation and 268 
Activities Questionnaire (OxPAQ) (56) and health-related quality of life as measured by EQ-269 
5D-5L (57).  In the longer term, we hypothesised that the intervention would reduce the impact 270 
of the Fatigue Impact Scale (MFIS-29) (58) and the physical and psychological impact of MS 271 
from the patient's perspective as measured by the Multiple Sclerosis Impact Scale (MSIS-29) 272 
(59). A further consideration was participant burden and the need for self-completion measures 273 
to facilitate the remote assessment.  Each of these measures have been validated for self-274 
completion by people with multiple sclerosis.   275 
 276 
After the baseline assessments have been completed by the participant, their online user 277 
account will be paired with an intervention physiotherapist’s account. This physiotherapist will 278 
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then contact the participant to arrange the first coaching session, after which the full LEAP-279 
MS online tool will be released to the participant. 280 
 281 
Participants will be asked to repeat the online patient-reported outcome measures, plus a 282 
modified Patients’ Global Impression of Change (PGIC) (60), at 3 months and 6 months post-283 
baseline. In this, they will be asked to indicate their degree of change using one of five 284 
responses (much better, slightly better, the same, slightly worse, much worse) in relation to 285 
their routine activities, emotional well-being and social engagement.  286 
 287 
Automatic prompts will be provided to the registration email address at the start of the follow-288 
up data collection window (2 weeks before and 2 weeks after the expected assessment 289 
completion date).  Participants will receive a telephone reminder if they have not logged on in 290 
the 2 weeks prior to the expected assessment completion date. Electronic data capture will be 291 
standardised across all study remote processes using an online platform developed by the 292 
Centre for Trials Research using a bespoke Structured Query Language (SQL) database. A 293 
study-specific data management plan has been developed to ensure the security and 294 
confidentiality of all participant data and that high-quality data is available for ongoing 295 
analyses. 296 
 297 
At the end of the initial intervention period (3 months) participants and their treating 298 
physiotherapists will be asked to participate in a semi-structured interview aimed at eliciting 299 
experiences and reflections on the intervention, and the process of its delivery (content, design, 300 
language, adaptability to personal needs and recommendations for the future). Given the small 301 
sample size of this feasibility study, everyone who consents to being interviewed will be 302 
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interviewed, even if they withdraw from the intervention (see process evaluation). Interviews 303 
will be conducted by a research team member who is not involved in the intervention delivery 304 
but is a physiotherapist by background and an experienced qualitative researcher. 305 
 306 
[Insert Table 1 here] 307 
Table 1: Schedule of enrolment, interventions and assessments  308 
 309 
 STUDY PERIOD 
 Screening Baseline Intervention Follow-up 
Timepoint -4 weeks - 0 0 0-3 months 3-6 
months 
3 months 6 months 
Screening       
Pre-screening – Eldrix 
HealthContact 
Database 




X      
Self-assessment online 
eligibility check 
X      
Eligibility screen & 
discuss the study 
(telephone call from 
research team) 
X      
Online informed 
consent 
X      
Eligibility confirmed at 
physiotherapy coaching 
session 
  X    
Intervention       
Physiotherapy 
coaching sessions (up 
to 6 sessions) 
  X    
LEAP-MS activity 
web-based platform 
  X X   
Assessments       
MFIS  X   X X 
MSIS-29  X   X X 
EQ-5D-5L  X   X X 
OxPAQ  X   X X 
UW-SES-SF  X   X X 
PGIC     X X 
Semi-structured 
interview 
    X  




LEAP-MS Intervention. The aim of the LEAP-MS intervention is to provide improved 311 
awareness of achievable, relevant and interesting activities and exercises for PwPMS. It will 312 
also provide an opportunity for sharing experiences of participating and enable shared 313 
management and monitoring (self and physiotherapist) of activities and exercises.  It is a 314 
blended physiotherapy intervention made up of 1) a co-produced, encrypted multi-user web-315 
based platform accessible to participants and physiotherapists and 2) coaching sessions with 316 
intervention physiotherapists delivered via a secure web video conferencing system, or in 317 
person, in the participant’s home.  Intervention physiotherapists are trained on self-318 
management principles and practice, use of technology in coaching sessions and physical 319 
activity and exercise guidelines for neurological conditions.   As this is a blended intervention 320 
including a web-based platform, participants will require computer skills (or a carer companion 321 
who can assist them is needed), and internet access for the duration of their study participation. 322 
 323 
The LEAP-MS online platform.  324 
The platform is specifically developed for PwPMS and includes regularly updated multimedia 325 
education about being active with PMS, tailored physical activity ideas and interactive 326 
functions enabling the development of personalised activity plans, goal setting and the 327 
monitoring of activity through activity logs.  Activities are displayed in an ‘activity suite’ 328 
grouped into categories e.g., cardiovascular, strengthening, balance, flexibility, pelvic health 329 
etc. and include a large range of exercise videos from aerobics to seated boxing to tai chi.  330 
These sit alongside other, more specific exercises described or demonstrated through text and 331 
images.  Each exercise or activity suggestion can be selected and added to an ‘activity plan’, 332 
enabling participants to select individual activities to try.  In addition, participants are able to 333 
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set and monitor personalised goals using a goal-setting function and input all activity 334 
undertaken through the use of an activity log.  A fuller description and images of the 335 
intervention is described elsewhere (53). 336 
 337 
The LEAP-MS platform enables access and data input options via desktop computers, laptops, 338 
tablets or smart phones. Participants, physiotherapists and the research team all have different 339 
access rights to and editing permissions for the LEAP-MS platform. Participants use the 340 
platform to register, complete eligibility forms, consent, baseline and follow-up measures, 341 
input safety information, as well as to access the interactive education and activity selection 342 
and planning tool. They are also enabled to contact their intervention physiotherapist via a 343 
messaging function to ask questions, seek guidance or request coaching sessions.  344 
Physiotherapists use the platform to record coaching session notes, respond to participant 345 
questions and requests and to view participant activity selections and goal setting. The platform 346 
is also used by the study team to evaluate participant engagement with the intervention and to 347 
manage data throughout the study.  348 
 349 
LEAP-MS coaching sessions 350 
LEAP-MS participants will meet with an intervention physiotherapist up to six times, remotely 351 
or face-face in their own homes.  During coaching sessions participants will be shown how to 352 
navigate and use the LEAP-MS online platform as required, select suitable activities, form an 353 
activity plan and set and review activity goals.  Drawing on both their professional knowledge 354 
and training underpinned by the Bridges self-management approach (61), people with MS are 355 
taught how to utilise self-efficacious and self-regulatory practices throughout the consultations.  356 
Critically physiotherapists will not instruct, or prescribe activity to participants – but instead 357 
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use coaching techniques and open questioning to consider meaningful activities they would 358 
like to try and support participants to set goals, log activity and monitor their progress.  Through 359 
discussion physiotherapists will support participants to identify potential barriers (e.g. their 360 
own motivation, habits, environmental or social factors) and pre-plan ways to overcome these 361 
barriers should they arise.  Following a mandatory initial coaching session, participants will be 362 
able to request up to five further coaching sessions and/or communicate via a messaging 363 
function described below. 364 
 365 
Participant use of the LEAP-MS platform and interaction with physiotherapists. 366 
In the initial 3-month intervention period, participant use of the LEAP-MS platform works in 367 
conjunction with support from intervention-trained physiotherapists and includes a user pairing 368 
facility where patient users are paired with an intervention physiotherapist. The physiotherapist 369 
can view the activity selections and goals set by the patient participant and provide coaching 370 
and support to engage with participants in setting small targets and incorporating physical 371 
activity into their everyday life. The web-based platform also has an inbuilt messaging function 372 
to enable participants to contact their physiotherapist in the initial 3-month period to ask 373 
questions, seek guidance about activity engagement and request up to six coaching sessions.  374 
Coaching sessions will be conducted at participant’s homes or online dependent on participant 375 
preference whilst accommodating any local restrictions (e.g. social distancing during COVID-376 
19 or staff availability - see (62) for Covid-19 study adaptations).  When conducted online, 377 
coaching sessions will be conducted via a secure web video conferencing system.  All 378 
interactions (whether in person, via web video conferencing or via the in-built platform 379 
messaging system) will operationalise a supported self-management approach to regular 380 
physical activity. Physiotherapists will not be required to respond immediately to 381 
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communication through the platform, but will schedule regular time slots to respond to LEAP-382 
MS communication, as they would with other forms of patient communication – such as 383 
returning telephone calls from outpatients or family members. They will aim to respond within 384 
5 working days. A pre-specified inactivity period 21 days on the website by any one participant 385 
will automatically be logged and flagged to the corresponding patient participant’s 386 
physiotherapist, who will then contact the participant to offer any further support.  387 
 388 
Interactions between participant and physiotherapist using the in-built platform messaging 389 
function will be captured by the study database. Notes of coaching sessions will be recorded in 390 
the web-platform and downloaded for adding to patient notes. Where face-to-face coaching 391 
sessions are conducted, intervention physiotherapists will be required to detail distance 392 
travelled, mode of travel time and face-to-face contact time.  For coaching sessions delivered 393 
via web video conferencing, only video conferencing time will be detailed. 394 
 395 
Physiotherapist Training. All intervention physiotherapists will receive bespoke LEAP-MS 396 
training, which delivers 1. real-time training (either face-face or remotely) about self-397 
management principles and how to integrate these into contacts with patients, 2. how to use 398 
online conferencing as a method of communication and providing consultations, 3. how to 399 
introduce/instruct patients in the use of online conferencing and online resources (in this case 400 
the LEAP-MS platform) and 4. a clinical update on physical activity and exercise guidelines 401 
for use with people with neurological conditions. The training package consists of real-time 402 
training days (delivered face-face or remotely) and an online self-study resource.  The real-403 
time self-management training workshops are delivered by experienced facilitators from 404 
Bridges Self-Management (http://www.bridgesselfmanagement.org.uk/).  Paper-based 405 
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learning materials traditionally accompanying face-face training workshops and video-406 
recorded films from the training have been digitised and housed in an online learning platform 407 
for use by intervention physiotherapists to refer back to as required.  Given the emergent 408 
challenges in rehabilitation service delivery during the COVID-19 pandemic, and the 409 
anticipated move to greater use of remote intervention delivery, further resources 410 
(https://www.bridgesselfmanagement.org.uk/covid-19-resources/) to help structure remote 411 
interactions were also made available as part of the final training package to ensure 412 
standardisation of coaching interactions regardless of mode of delivery (online or face to face 413 
in the home). In addition, an accompanying online training resource included video-recordings 414 
with experienced physiotherapists with expertise in the use of digital technologies in practice 415 
to provide guidance on use of technology in coaching sessions and videos with an expert in 416 
exercise prescription for people with neurological conditions to teach core principles of 417 
exercise physiology and prescription (63,64). Intervention physiotherapists are required to 418 
watch and work through these additional learning materials independently. 419 
 420 
The physiotherapists who complete the training will be invited to participate in the LEAP-MS 421 
study as ‘intervention physiotherapists’. All those who consent to taking part will have access 422 
to conversation-based scripts that they can use to guide their coaching conversations (primarily 423 
for online use). They will also have the opportunity to practice coaching conversations and 424 
receive peer review. They will be asked to take part in interviews to share their experience of 425 
intervention training and intervention delivery.  426 
 427 
Safety. We will assess and record any adverse events that may be reported. 428 
LEAP-MS: Protocol for a Single-Arm Feasibility Study. 
 
20 
Expected Adverse Events (AEs): In this patient population, hospitalisation due to MS, acute 429 
illness resulting in hospitalisation, new medical problems and deterioration of existing medical 430 
problems are expected. This information will be self-reported by patients online and will not 431 
be subject to expedited reporting, however, it will be reviewed on a monthly basis by the study 432 
team. The physical activity intervention does not specifically involve any heavy load-bearing 433 
exercise or heavy eccentric muscle activity. However, some minor muscle soreness or muscular 434 
strain may occur in the few days following the initiation of a new exercise programme or 435 
increased physical activity. This would normally resolve spontaneously and would not require 436 
any specific interventions or additional medical care but will be noted as a potential expected 437 
related AE if reported during the 3-month intervention period.  Falls and fatigue are an expected 438 
AE as part of the clinical condition but will be monitored for the duration of the intervention.  439 
 440 
Procedure: Participants will be asked to use the LEAP-MS platform to self-report any incidents 441 
of falls, fatigue, increased muscle soreness or sprain, or other incident they feel is relevant, and 442 
whether the incident required medical intervention. Selecting that medical intervention was 443 
required will trigger an automated prompt to the paired physiotherapist. Similarly, no activity 444 
on the online platform for 3 weeks will also trigger an automated prompt to the paired 445 
physiotherapist. Once prompted, the paired physiotherapist will contact the participant to 446 
discuss the incident. All serious adverse events (SAEs) that occur between the time of consent 447 
and the 3 months follow-up must be reported immediately to the Centre for Trials Research 448 
(within 24 hours of knowledge of the event) by the intervention therapist using a dedicated 449 
SAE form, unless the SAE is specified as not requiring immediate reporting. 450 
 451 
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Planned Analyses. Analyses will be guided by the CONSORT extension for pilot and 452 
feasibility studies (65). The primary objectives are to establish feasibility of the study in terms 453 
of quantitative measures of recruitment, retention, intervention uptake and safety (see Table 2).  454 
All proportions will be tabulated with 95% confidence intervals alongside the CONSORT 455 
chart, which will detail the reasons for exclusion, refusal and dropout. Intervention uptake will 456 
be reported descriptively. There is no defined minimum dataset for the clinical secondary 457 
outcomes. Data completeness of each patient-reported outcome measure will be tabulated and 458 
will further inform our assessment of feasibility. Distributions of the outcomes scores will be 459 
investigated and appropriate summary measures for the whole group tabulated with 95% 460 
confidence intervals at baseline and follow-up time points.  An assessment of attrition bias will 461 
be made via tabulation of baseline characteristics for those with complete follow-up data and 462 
those who were not followed-up. No formal hypothesis tests will be carried out in the analyses, 463 
however factors such as disease severity (as represented by EDSS scores) and self-efficacy 464 
(measured by UW-SES) that may plausibly impact on adherence and retention will be explored 465 
with graphical displays. The traffic light system (green, amber, red) of progression criteria as 466 
proposed by Avery et al (2017) (66) will be utilised (see Table 2) to guide our decisions as to 467 
future evaluations.  468 
 469 
[Insert Table 2 here] 470 
 471 




Green Amber Red 
Recruitment  Percentage of those 
submitting online 
70% 50 - 69% Less than 
50% 
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permission to contact 
forms who are eligible 
and who consent to 
participation. 
Retention   Percentage of 
individuals who 
complete the 3-month 
follow-up 
assessments. 
70% 50 - 69% less than 50% 
 473 
If at the end of the study the feasibility progression criteria are achieved, then the 474 
recommendation would be to move to a randomised evaluation. Modifications in the trial 475 
processes or the intervention may be required if progression criteria are not fully achieved. If 476 
there is not an identifiable reason or remediable action that can be taken, then progression to a 477 
full trial would not be recommended.  478 
 479 
Intervention uptake and safety are not formal progression criteria in this single arm feasibility 480 
study but will be closely monitored and considered in any final recommendations for further 481 
evaluations. Intervention uptake will be reflected by 1. the percentage of initial coaching 482 
sessions completed, number of additional physiotherapy coaching sessions requested and 483 
completed, and the number of remote physiotherapist contacts recorded and 2. frequency and 484 
duration of weekly logged physical activity. Website log in rates and length of time between 485 
each log in episode will provide supplemental information on intervention uptake. Safety will 486 
be assessed using an online process of self-reporting by the participant and from any SAE 487 
forms completed by the intervention therapist.   488 
 489 
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PROCESS EVALUATION  490 
The process evaluation will enable an understanding of the acceptability and fidelity of the 491 
intervention, identify possible mechanisms for any observed effects and learn about any 492 
adaptations made by the participants (PwPMS and physiotherapists) in undertaking the 493 
programme. Acceptability assessment will focus on content, design, language and adaptability 494 
to personal needs. It will be assessed through the analysis of any remote contact between 495 
participants and physiotherapists as well as semi-structured interviews (conducted either face 496 
to face or via the secure web video conferencing system) with participants who completed the 497 
intervention, those who withdraw from the study and physiotherapists who deliver the 498 
intervention. In physiotherapist interviews, we will collect detailed demographic information 499 
so we can understand how their characteristics (work setting, previous experience, previous 500 
training) influences their approach, experience of the training and delivering the intervention.  501 
 502 
Fidelity of the LEAP-MS intervention delivery will be assessed using independent analysis of 503 
audio-recorded and/or observed (sampled) sessions, analysis of participants’ online activity 504 
logs and participant-physiotherapist communications. Six initial coaching sessions 505 
(approximately 25% of initial coaching sessions) and between 5 and 10 follow-up coaching 506 
sessions (dependent on participant consent) will be observed and audio-recorded if conducted 507 
face-face.  Coaching sessions conducted via web video conferencing, will be recorded using 508 
an in-built recording function.   509 
 510 
Actions observed during face-face observations will be captured using basic proxemic sketches 511 
(stick people drawings), kinesics (Kinesics refers to the nonverbal movement related elements 512 
of communication in the creation and sustaining of social interactions), alongside standard 513 
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ethnographic notations (the description of actions/happenings as the observer sees them) (67).  514 
The proxemic and kinesics sketches will serve to record the physical and spatial interactions 515 
between patient, physiotherapist and intervention technology, to assist the charting of how 516 
learning is delivered and ‘gets done’ through the coaching sessions.  If the intervention is 517 
delivered remotely, coaching sessions will be recorded and analysed directly.  518 
 519 
This range of data collection methods has been selected to enable a comprehensive and multi-520 
faceted description of the experience of those taking part, a nuanced understanding of 521 
intervention delivery and usage.  The multiple methods selected will also act as a robust form 522 
of triangulation. 523 
 524 
All qualitative data collection for the process evaluation will be carried out by a research team 525 
member with qualitative research experience, not involved in intervention delivery.  All data 526 
will initially be separated into their ‘type’, i.e. speech, text or action (observation), with 527 
appropriate methods of analysis applied to each type of data. Interviews, recorded coaching 528 
sessions and observations will be analysed thematically initially (68).  Should the coaching 529 
sessions component of the intervention be found to be central to the usage of the online 530 
platform, discourse analysis may be conducted to better capture and understand the impact of 531 
interaction and communication between patient participant and physiotherapist. Data collected 532 
from text-based online interaction (emails between patient participant and physiotherapist, goal 533 
setting and activity records) will be considered as ‘personal documents’ and subject to textual 534 
analysis methods.   535 
 536 
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Due to the focus of this process evaluation on the use of each component of the intervention, 537 
the personal documentation will be initially subjected to content analysis – with a more detailed 538 
thematic analysis applied if required (69), to assist final synthesis and triangulation should the 539 
depth of the data warrant it.  Key findings from each type of data set will be compared and 540 
contrasted, drawing out similarities, differences and any contradictions. Data will be reviewed 541 
in light of any contradictions and will guide a member checking process with participants, 542 
which will be conducted prior to the write-up and dissemination of findings.  543 
 544 
Findings will be separated into process and outcome data ready for reporting but with 545 
consideration being given to where/if the doing of any process is a major contributor to the 546 
outcomes or perceived experience of participants. At this point, we will explore possible 547 
mechanisms for any observed effects (both for the person with MS and the intervention 548 
physiotherapist) so as to validate change objectives, behavioural outcomes and patient-reported 549 
intermediate and longer-term outcomes as depicted in the proposed intervention logic model 550 
(Figure 2). There are training needs for physiotherapy staff in delivering this intervention.  551 
These are reflected in the physiotherapy component of the logic model as are aspects related to 552 
the broader context within which this intervention will be implemented. 553 
 554 
[Insert Figure 2] 555 
 556 
Figure 2: LEAP-MS Intervention logic model detailing objectives, activities and outcomes of 557 
PwPMS and the intervention physiotherapist. 558 
 559 




The LEAP-MS platform is a multi-user system enabling participants and physiotherapist to co-561 
create activity plans. The LEAP-MS platform consists of an information and activity suite, 562 
interactive components enabling selection of exercises to create an activity programme, goal 563 
setting, and activity logging. The platform also facilitates remote support from a 564 
physiotherapist through an embedded online messaging function. Our experience here lays the 565 
basis for the development of multi-user platforms that can be adapted according to population 566 
and trial design.  567 
 568 
As the secure, encrypted multi-user web-based platform will be accessible to participants, 569 
physiotherapists and researchers with data input options via desktop computers, laptops, tablets 570 
or smart phones, participants are able to use the platform to register, complete eligibility forms, 571 
consent, baseline and follow-up measures as well as to access the intervention. Participants, 572 
physiotherapists and research administrators all have different access and editing level 573 
permissions within the platform. It is also used by the study team to evaluate participant 574 
engagement with the intervention and to manage data throughout the study. 575 
 576 
Our ambition has been to co-design a model for physical activity self-management support for 577 
PwPMS that is patient-, family/carer- and community-centred with physiotherapists providing 578 
a unique role as a coach and partner throughout the whole disease trajectory (70). Self-579 
management approaches are associated with a reduced reliance on health professionals and an 580 
increased sense of autonomy and control over an individual’s condition.  Such approaches are 581 
also characterised by upskilling the individual to anticipate potential barriers to achieving any 582 
specified goals and to problem solve in the face of such challenges.  Any programme, based 583 
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on self-management principles should then, at its heart, address the fundamental, individual 584 
and relational barriers that typical physio-led interventions may pose. Upskilling 585 
physiotherapists’ self-management support skills alongside exercise prescription knowledge, 586 
sharing expertise and working collaboratively with people living with progressive MS to define 587 
strategies and activity plans is more likely to promote physical activity behaviour change (71).  588 
 589 
Unlike other physiotherapy-based online activity platforms for other conditions or general 590 
education platforms, the LEAP-MS platform has a paired account function in which people 591 
with MS can be paired with their physiotherapist. Critically, rather than the physiotherapist 592 
selecting and prescribing activities, the person with MS has complete choice and control of this 593 
process. The physiotherapist can view participant activity logs, but advise only as required by 594 
the person with MS.  Furthermore, the patient-facing element of the LEAP-MS intervention 595 
platform combines multimedia educational content, activity provision, activity monitoring and 596 
goal setting. It includes an online hub for physiotherapists, which draws together self-597 
management training and provides a space for multimedia exercise in long-term neurological 598 
conditions.  599 
 600 
Evaluation of feasibility, including intervention uptake as measured by login rates and duration, 601 
and acceptability in terms of content, design, language and adaptability to personal needs will 602 
inform modification and future evaluation.  Findings from the feasibility study will be 603 
disseminated to participants, health care professionals and the public via a series of outputs.  604 
These include a lay summary of findings to be sent to participants and published on university 605 
and funder websites for public viewing, formal research reports, peer-reviewed publications 606 
and conference papers to share findings with health care professionals.  607 
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LIST OF ABBREVIATIONS 608 
 609 
LEAP-MS Lifestyle, Exercise and Activity Package for 
people with Multiple Sclerosis 
 
MS Multiple Sclerosis 
 People with progressive MS 
 
DVD digital versatile disc 
 
EDSS Expanded Disability Status Scale 
 
MFIS Modified form of the Fatigue Impact Scale 
(MFIS) 
 
MSIS-29 Multiple Sclerosis Impact Scale  
 
EQ-5D-5L (a health-related quality of life outcome 
measure) 
OxPAQ Oxford Participation and Activities 
Questionnaire  
 
UW-SES University of Washington 6-item short form 
self-efficacy scale  
 
PGIC Patients’ Global Impression of Change 
 
AE Adverse Event 
 
SAE Serious Adverse Event 
 
NHS National Health Service  
 
SPIRIT Standard Protocol Items: Recommendations 
for Interventional Trials 
TIDIeR Template for Intervention Description and 
Replication 
CONSORT Consolidated Standards of Reporting Trials 
  610 
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TRIAL STATUS 611 
The trial is sponsored by Cardiff University (resgov@cardiff.ac.uk) and is set up. Recruitment 612 
will commence on 01.06.2020 and is anticipated to end in 30.09.2020. This manuscript has 613 
been drafted according to version 1.1 (12/05/2020) of the trial protocol. The protocol has been 614 
written according to the Standard Protocol Items: Recommendations for Interventional Trials 615 
(SPIRIT) statement (see Figure 2 and Additional File 1); the intervention is described according 616 
to the Template for Intervention Description and Replication (TIDieR) checklist (see 617 
Additional File 2); and the final report will follow the Consolidated Standards of Reporting 618 
Trials (CONSORT) statement (Extension for Pilot and Feasibility Studies). Study results will 619 




Ethics approval and consent to participate 624 
This study was approved on 25th June 2019 by the Research Ethics Committee (REC) For 625 
Wales (Wales REC 6), recognised by the United Kingdom.  Ethics Committee Authority 626 
(UKECA). REC reference: 19/WA/1095. This centralised Ethics Committee approved the 627 
study in all the sites. All sites within the UK received research and development (R&D) 628 
approval from the appropriate Health Boards. Study participants will provide informed consent 629 
via the online platform (see methods section).  630 
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